Skip to main content

Watson enters marketing agreement with GeneraMedix


MORRISTOWN, N.J. Watson Pharmaceuticals has entered an exclusive U.S. marketing agreement with a generic drug maker for its branded anemia drug.

Watson, which mostly manufactures generics, announced Tuesday that it had granted GeneraMedix a license for a generic version of the injected drug Ferrlecit (sodium ferric gluconate complex in sucrose). Under the agreement, GeneraMedix, which has filed an approval application with the Food and Drug Administration for generic Ferrlecit, will supply its version to Watson, which will market, sell and distribute it in the United States. Terms of the agreement were not disclosed.

Watson markets branded Ferrlecit under a supply and distribution agreement with Sanofi-Aventis. The product rights for Ferrlecit will return to Sanofi on Dec. 31.

This ad will auto-close in 10 seconds